CBD gummies have become a staple on Irish shelves, sold in pharmacies and health shops across Dublin, Cork, and Galway. Once a niche product, they now sit alongside vitamins and herbal supplements, marketed as aids for stress, sleep, and joint discomfort. Their rise in popularity stems partly from convenience: pre-dosed, portable, and free of the bitter taste that often deters people from CBD oil. However, the rapid growth has outpaced public understanding of what the product actually delivers.
The compound at the center of this trend, cannabidiol (CBD), is one of over a hundred cannabinoids found in the hemp plant (Cannabis sativa). Unlike THC—the psychoactive compound in cannabis that causes a “high”—CBD does not produce euphoria or impairment. The World Health Organization’s Expert Committee on Drug Dependence reviewed the compound in 2018 and concluded that CBD “exhibits no effects indicative of any abuse or dependence potential” and is “generally well tolerated with a good safety profile.” This distinction explains why regulators treat CBD differently from cannabis itself.
How CBD Interacts with the Body
CBD’s effects are thought to work primarily through the endocannabinoid system, a network of receptors and signaling molecules that helps regulate mood, sleep, appetite, pain, and stress responses. Rather than binding strongly to cannabinoid receptors the way THC does, CBD appears to modulate them indirectly and interacts with serotonin (5-HT1A) receptors, which may partly explain its reported effects on anxiety. The strongest evidence for CBD’s biological activity comes from medical contexts: a purified CBD medicine, Epidiolex, has been approved by the US FDA and the European Medicines Agency for treating rare childhood epilepsies.
For consumer products like gummies, however, the science is less clear. The most studied use case is anxiety. A 2011 trial in Neuropsychopharmacology found that a single 600 mg dose of CBD reduced anxiety in people with social anxiety disorder during a simulated public-speaking test. Participants reported less cognitive impairment and discomfort than those given a placebo, though the doses used in research far exceed what’s typically found in a gummy—usually between 10 mg and 25 mg.
Sleep and everyday anxiety have also been explored, but with more limited evidence. A 2019 case series in The Permanente Journal followed 72 adults with anxiety or sleep issues, reporting improvements in 79% for anxiety and 66% for sleep within a month. However, the study lacked a placebo group, and sleep scores fluctuated over time. The results are suggestive, not definitive.
Pain relief presents an even murkier picture. Systematic reviews consistently find stronger evidence for combined THC/CBD medicines in specific conditions like multiple-sclerosis spasticity, while trials of CBD alone for chronic pain have produced inconsistent results. Many studies find effects that are modest or indistinguishable from placebo, a nuance often omitted in marketing claims.
Regulatory Concerns and Safety Limits
Regulators have grown increasingly cautious about daily intake limits. In 2023, the UK’s Food Standards Agency reduced its advisory limit for healthy adults from 70 mg to just 10 mg of CBD per day. The European Food Safety Authority followed in 2026 with a provisional safe intake level of around 0.0275 mg per kilogram of body weight per day, roughly 2 mg daily for a 70 kg adult. The authority stressed significant gaps in long-term safety data, particularly for the liver, hormones, and nervous system, and stated it could not establish safety for people under 25, pregnant or breastfeeding women, or those on medication.
The most pressing consumer risk, however, is not the CBD itself but the lack of transparency in product contents. Independent testing has repeatedly found that many products do not match their labels. A BBC analysis revealed that only a minority of tested CBD products contained the advertised amount of CBD, with some containing little or none despite premium pricing. Others have been found to include THC above legal limits. For consumers, this means the difference between an underdosed product and one that meets its claims, and why so many first-time users dismiss CBD as ineffective.
Ensuring Product Quality and Safety
To mitigate this risk, experts recommend buying only from companies that publish independent, third-party laboratory reports, known as Certificates of Analysis. These confirm both the CBD content and the absence of THC, heavy metals, and pesticides. Reputable brands make these reports easy to find; if a seller cannot provide one, it should raise concerns.
In Ireland, the legal status of CBD remains complex despite its widespread sale. Under EU rules, CBD extracts are classified as a “novel food,” requiring pre-market authorization. The Food Safety Authority of Ireland (FSAI) states plainly that CBD is currently an “unauthorised novel food” and therefore cannot lawfully be placed on the market as, or in, food or food supplements. Multiple applications are still under EU review. Meanwhile, THC remains a controlled substance, so any product must be THC-free or within strict trace limits.
Handling CBD Purchases in Ireland
For shoppers, two key rules apply. First, since CBD is regulated as a food supplement, not a medicine, it is illegal for sellers to make medical or health claims. Any brand promising to “cure anxiety” or “treat pain” should be viewed skeptically. Second, consumers should prioritize established Irish or EU brands with transparent testing, clear labeling, and accessible customer service over anonymous overseas sellers.
Waterford-based Dr. Hemp Me, for instance, publishes independent lab results for every product, offers THC-free broad-spectrum gummies with clearly stated doses, and provides a money-back guarantee. Such transparency is becoming more common in the Irish market, distinguishing informed wellness purchases from untested risks.
